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Polyomaviruses are widely distributed in vertebrates. The era of polyomavirus 
began with the accidental discovery of murine polyomavirus (MPyV) in 1958 followed 
by the discovery of simian virus 40 (SV40) in 1960 in monkey kidney cells that were 
used to prepare the polio vaccine (267, 270). The name polyomavirus is derived from 
the Greek words poly: many and oma: tumor following the observation that tissue 
extracts containing MPyV caused the development of multiple tumors when injected 
into newborn mice.  A decade later, the two human viruses JC polyomavirus (JCPyV) 
and BK polyomavirus (BKPyV) were independently discovered in 1971 (100, 219). 
BKPyV was isolated from the urine of a kidney transplant (KT) patient with the initials 
B.K. suffering from ureteric stenosis while JCPyV was isolated from the brain of a 
patient with the initials J.C. who died of progressive multifocal leukoencephalopathy 
(PML). Both viruses were isolated using cell culture and visualized by electron 
microscopy, a novel technology at that time. It took approximately 40 years for the 
next discovery of human polyomaviruses. In 2007, KI polyomavirus (KIPyV) and WU 
polyomavirus (WUPyV) were isolated independently from the nasopharyngeal 
aspirates of patients presenting with respiratory infections (9, 103). While KIPyV was 
identified by cloning of DNase protected deoxyribonucleic acid (DNA) followed by 
random polymerase chain reaction (PCR) and conventional sequencing, WUPyV was 
identified by generation of a random library followed by high throughput DNA 
sequencing. The names KI and WU were derived from the initials of the institutes 
where the viruses were discovered. Since then, in just 6 years, 8 more human 
polyomaviruses were described. This sudden increase in the number of human 
polyomaviruses was due to the increased awareness and advances in molecular 





merkel cell cancer tissue by digital transcriptome subtraction (90). In 2010, Human 
polyomavirus 6 and 7 (HPyV6 and HPyV7) were detected by amplification of circular 
DNA from skin swabs from healthy individuals using random hexamer-primed rolling 
circle amplification and followed by cloning and sequencing (249). In the same year, 
trichodysplasia spinulosa-associated polyomavirus (TSPyV) was detected by rolling 
circle amplification, cloning and sequencing of circular DNA from the spicules of a 
immunosuppressed heart transplant patient with the rare skin disease trichodysplasia 
spinulosa (279). In 2010, Human polyomavirus 9 (HPyV9) was discovered in the 
serum of a KT patient by the use of a degenerated PCR targeting the VP1 gene 
(250). Human polyomavirus 10 (HPyV10) was discovered by rolling circle 
amplification, followed by cloning and sequencing of DNA from some condylomas 
from a patient with a rare skin disorder (47). The two variants of this virus, Malawi 
polyomavirus (MWPyV) and MX polyomavirus (MXPyV) were discovered in stool 
specimens of children suffering from diarrhea by performing shotgun pyrosequencing 
of purified viral particles or unbiased deep sequencing of cDNA libraries, respectively 
(262, 292). Saint Louis polyomavirus (STLPyV) was also discovered in a stool 
specimen of a child with diarrhea by the use of rolling circle amplification followed by 
pyrosequencing (179). Recently, Human polyomavirus 12 (HPyV12) was detected by 
generic PCR of DNA from liver samples of patients who underwent surgery, followed 
by nested long-distance PCR and sequencing (166). Very recently, New Jersey 
polyomavirus (NJPyV-2013) was detected in endothelial cells from a muscle biopsy 
of a pancreas-transplant patient suffering from retinal blindness and vasculitic 
myopathy by the use of  high-throughput nucleic acid sequencing (197). So far, 13 
different human polyomaviruses have been described. Even though all the human 





causal role for disease has only been established for BKPyV, JCPyV, MCPyV and 
TSPyV (62).  
Classification  
The classification of polyomavirus has changed in recent years. In the first 
classification, polyomavirus was classified within the Papopaviridae family together 
with papillomavirus. In 2000, the International Committee on Taxonomy of Viruses 
split the Papopaviridae family into the two families Polyomaviridae and 
Papillomaviridae. Polyomaviridae consists of only one genus: polyomavirus. Due to 
the increasing number of polyomaviruses and their biological and genomic 
differences, in 2007 the International Committee on Taxonomy of Viruses formed the 
Polyomaviridae Study Group to revise the classification again. Accordingly, in 2010 
the Polyomaviridae Study Group recommended a reclassification based on the host 
range, genetic repertoire and DNA sequence identity over the whole genome (150). 
This new classification would divide the current single genus into two mammalian 
genera (Orthpolyomavirus and Wukipolyomavirus) and one avian genus 
(Avipolyomavirus). Interestingly, all the polyomavirus known to cause diseases would 
belong to the genus orthopolyomavirus. However, the suggested classification was 








BK and JC polyomavirus 
 Virion Structure 
Polyomaviruses are morphologically indistinguishable and share common 
structural characteristics. They are non-enveloped and small, measuring 
approximately 40-45 nm in diameter. The capsid is composed of 72 pentameric VP1 
capsomers arranged in icosahedral symmetry (T=7) and encloses the viral genome 
(Figure 1). Each capsomer under its surface contains one molecule of either VP2 or 
VP3. The virion consists of 88% protein and 12% DNA (6).  
 
Figure 1. Polyomavirus Virion. Schematic illustration of polyomavirus virion 
showing  the organization of capsid proteins enclosing double stranded DNA genome 
wrapped around histones (ViralZone: www.expasy.org/viralzone, Swiss Institute of 
Bioinformatics).  
Genome  
The BKPyV and JCPyV genomes consist of a single copy of circular, double 
stranded DNA of approximately 5.2 kilo base pairs (bp) with a molecular weight of 
approximately 3.2 X106 Dalton (6). Inside the capsid, the genome is associated with 
cellular histones to form about 21 nucleosomes like a minichromosome (58, 193). 
Each nucleosome contains two copies of the four different cellular histones H2A, 





use of overlapping open reading frames and frame shifts and by the use of internal 
translation initiation codons. There is approximately 75% sequence identity between 




Figure 2. Schematic illustration of the circular double stranded DNA genome of 
archetype BKPyV WW (Gen Bank AB211371.1) (A) (modified from (234)) and of 
archetype JCPyV CY (Gene Bank  AB038249) (B). The common genome 
organization shows the early- and late viral gene region separated by the regulatory 
non-coding control region (NCCR) containing numerous transcription factor binding 
sites. Arrow indicates the direction of transcription of the gene and the dash (-) 
indicates a pre-microRNA (miRNA) that generates two miRNAs.  The NCCR of 
BKPyV is divided into 5 different sequence blocks denoted O, P, Q, R and S where 
the O block contains the origin of replication. The NCCR of JCPyV is divided into 6 
blocks denoted A, B, C, D, E and F in addition to Ori block containing the origin of 






 Like other polyomaviruses, the BKPyV (Figure 2A) and JCPyV (Figure 2B) 
genomes are functionally divided into 3 different regions: an early viral gene region, a 
late viral gene region and a non-coding control region (NCCR). 
The early viral gene region is located upstream of the origin of replication. The 
early viral gene region encodes early proteins Large Tumor antigen (LTag) and small 
Tumor antigen (sTag). In addition, the early viral gene region of BKPyV encodes a 
truncated T antigen (TruncTag) while that of JCPyV encodes T’135, T’136 and T’165 
antigens (1, 272). This means that BKPyV and JCPyV express 3 and 5 different early 
proteins, respectively. All these proteins are translated from mRNAs produced by 
alternative splicing of a single, large transcript (pre-mRNA).  
The late viral gene region on the downstream side of the origin of replication 
encodes the late proteins VP1, VP2, VP3 and agnoprotein. So far, BKPyV and 
JCPyV are the only human polyomaviruses encoding agnoprotein. Like early 
proteins, the late proteins are also translated from an alternatively spliced pre-mRNA. 
Transcription of the late region occurs in the opposite direction and from the strand 
complementary to that used for early transcription. VP2 and VP3 are translated from 
alternative start codons on a common mRNA transcript in the same reading frame 
while VP1 and agnoprotein are translated in a different reading frame (145, 154).  
The NCCR is located between the translation start codons for the early genes 
and late genes and is a nucleosome free region of the genome (234). The NCCR 
typically contains the origin of replication, the binding sites for LTag, promoter and 
transcription enhancer elements and thus, contains the regulatory information for 
transcription of the genes (198). The specific host cell tropism is also at least in part 





people, BKPyV WW and JCPyV CY contain the archetype NCCR and are considered 
to be the transmissible strains (67, 85, 111, 117). The archetype NCCR of BKPyV 
WW has been arbitrarily divided into five sequence blocks, O (142bp), P (68bp), Q 
(39bp), R (63bp) and S (63bp) (Figure 2A) where the origin of replication is located 
in the O block. Similarly, the archetype NCCR of JCPyV CY is arbitrarily divided into 
six blocks A (36bp), B (23bp), C (55bp), D (66bp), E (18bp) and F (69bp) in addition 
to Ori (117bp) containing the origin of replication (Figure 2B) (188, 198). Deletion, 
duplication and rearrangement of the NCCR blocks may occur during replication and 
the NCCR is then referred to as a rearranged NCCR. The rearranged NCCR has 
often been linked with a high replication capacity in vitro and in vivo and therefore 
also with disease (110, 111, 213).  
Viral proteins 
Table 1. An overview of viral proteins of BKPyV Dunlop (GenBank V01108) and 
JCPyV CY (GenBank AB038249) and their % identity (modified from (6, 72, 144)) 
Viral Proteins Cellular 
localization 
Number of aminoacids 
BKPyV/JCPyV 




Early     
LTag Nucleus 695/688 80.5/79.3 83% 
sTag Nucleus/ 
Cytoplasm 
172/172 20.5/20.2 78% 
TruncTag Nucleus 135/- 17/-  
T’ 165 antigen  Nucleus -/165 -/NA  
T’ 136 antigen Nucleus -/136 -/NA  
T’ 135 antigen Nucleus -/135 -/NA  
Late     
VP1 Nucleus 362/354 40.1/39.6 63% 
VP2 Nucleus 351/344 38.3/37.4 80% 
VP3 Nucleus 232/225 26.7/25.7 77% 
Agnoprotein Cytoplasm/ 
Perinuclear 
66/71 7.4/8.1 63% 






Large T antigen: LTag which is the major regulatory protein localizes to the 
nucleus and has multiple functions in the viral replication cycle including initiation of 
DNA replication, the translation of late genes and autoregulation of early genes.  In 
addition, LTag regulates the cell cycle. Most of the knowledge of LTag functions is 
derived from SV40 LTag studies. Since SV40 LTag shares more than 70% 
aminoacid identity to LTags of BKPyV and JCPyV, this suggests the common LTag 
functions (Table 1) (6). Figure 3 illustrates the functional domains and major binding 
sites of SV40 LTag for cellular proteins: such as the N-terminal J domain, responsible 
for binding with heat shock protein 70 and with DNA polymerase α (Pol α) important 
for viral DNA replication; the protein retinoblastoma (pRB) binding domain with the 
LXCXE motif, responsible for binding with the member proteins of pRB family;  the 
Ori binding domain, responsible for binding with the origin of replication in NCCR and 
with a binding site for topoisomerase I, required for relaxation and reannealing of 
DNA strands; the Helicase domain, responsible for unwinding of double stranded 
DNA during replication and with a binding site for Pol α; the Zn finger region, 
responsible for oligomerization of LTag; the bipartite p53 binding domain, responsible 
for binding with p53; the ATPase domain, responsible for ATPase activity of LTag; 
the host range domain, responsible for the host range function and virion assembly; 
and the Nuclear Localization Signal, responsible for the nuclear translocation of LTag 







Figure 3. Schematic illustration of SV40 LTag (modified from (268, 282)). 
The organization of functional domains and binding sites for the host cell proteins are 
shown such as J domain, LXCXE motif of pRB binding domain, Nuclear Localization 
Signal (NLS), Ori binding domain, Zn finger region (Zn), Helicase domain, bipartite 
p53 binding domain, ATPase domain, and the host range (HR) domain and the 
binding sites for cellular proteins heat shock protein (Hsc70), pRB, p107, p130, p53, 
DNA polymerase α (Pol α) and Topoisomerase I.  
 
The interactions between LTag and cellular proteins are crucial for creating an 
intracellular environment conducive to viral replication. I will discuss a few of these 
interactions in detail here to illustrate this point while the direct involvement with viral 
genome replication will be discussed under viral replication. As mentioned above, 
SV40-, BKPyV- and JCPyV-LTags interact with pocket proteins of tumor suppressor 
pRB family (pRB, p107 and p130) and p53 (285). The pocket proteins of the pRB 
family are the key regulators of the cell cycle. The transcription factors of the E2F 
family induce expression of cellular genes that are essential to mediate S phase 
entry. Normally, hypophosphorylated pRB binds and inhibits these transcription 
factors, while phosphorylated pRB releases the factors. In this way, pRB regulates 





family transcription factor complex and releases the E2F transcription factors, 
thereby mediating transition from G1- to S phase. Induction of S phase, the cellular 
DNA synthesis phase, is very important for viral DNA synthesis. The p53 is also a 
potent transcriptional activator that induces the expression of a number of cellular 
genes, some of which mediate DNA repair, cell cycle arrest or apoptosis (7). Under 
normal conditions, p53 is maintained at a low level by binding with the promoter of 
the mdm2 gene and stimulating its transcription. The Mdm2 protein then binds p53, 
inducing its polyubiquitination and subsequent degradation (7). During cellular stress 
such as DNA damage, this interaction is perturbed and the level of p53 increases 
leading to DNA repair, cell cycle arrest and possibly apoptosis. In polyomavirus 
infected cells, however, LTag interacts directly with p53 and block both its negative 
feedback loop with Mdm2 and its primary regulatory functions, thus preventing cell 
cycle arrest and apoptosis (reviewed in (7)).  
In addition to the multitude of functions described above, SV40 LTag undergoes 
many post-translational modifications, such as phosphorylation, glycosylation, ADP-
ribosylation, acetylation, adenylation and acylation,  possibly further modifying  its 
functions (58, 224).  
Small Tumor antigen: sTag is also a regulatory protein that localizes to both 
the nucleus and cytoplasm of the infected cells and shares N-terminal region with 
LTag (70, 86, 222). The function of sTag is still not resolved in detail but most of the 
functions were identified from the studies of SV40 sTag. The BKPyV and JCPyV 
sTags share 71 and 68% amino acid identity with SV40 sTag, respectively (Table 1) 
(6) and this high aminoacid identity  suggests that sTags of these viruses have 
common functions. Like SV40 sTag, JCPyV sTag was also reported to interact with 





by dephosphorylation and in this way, sTag is indirectly involved in the viral genome 
replication and also in cell transformation particularly in the setting of low LTag level 
(36, 220, 222).  
Other T antigens: The JCPyV T’135, T’136 and T’165, collectively referred to 
as JCPyV T’ags where the numbers indicate the number of aminoacids, share 132 
aminoacids with the N-terminal region of LTag containing the J domain, the pRB 
binding domain and the nuclear localization signal. These proteins localize to the 
nucleus and interact with pRB proteins via the LXCXE motif and are probably 
involved in cellular transformation and viral DNA replication (37, 225). The BKPyV 
truncTag  also shares 133 aminoacids with the N-terminal region of BKPyV LTag and 
is structurally similar to JCPyV T’ags (1), suggesting that truncTag may have 
functions similar to those of JCPyV T’ags.  
VP1: VP1 is the major structural protein and contributes 75% of the total virion 
protein mass (40). During viral replication, it localizes to the nucleus and forms the 
capsid or outer shell of the virion. In the capsid, 360 VP1 monomers are arranged in 
72 pentamers. The flexible C-terminal end of VP1 connects each pentamer to other 
pentamers by hydrophobic bonds which are further strengthened by disulfide bonds 
(58). In addition to being  crucial for capsid formation,  VP1 is also important for the 
genome packaging during virus assembly (reviewed in (217)). Moreover, the VP1 
contains a variable antigen binding region, which serves as the ligand for viral 
attachment to host cells (81, 148).  
VP2 and VP3: VP2 and VP3 are minor structural proteins and also localize to 
the nucleus of infected cells. In the virion, VP2/VP3 functions as a bridge to connect 





VP2/VP3 was shown to interact with LTag and increase binding to the origin of 
replication thereby enhancing the replication of viral DNA (242). In addition, an 
essential role of VP2/VP3 in the packaging of JCPyV DNA has been suggested 
(101).  BKPyV and JCPyV share 80 and 77% amino acids identity in VP2 and VP3, 
respectively (Table 1) (6) thus suggesting for similar functions. 
Agnoprotein: Agnoprotein is a non-structural protein that localizes mainly to 
the cytoplasm and the perinuclear region although a minor fraction is detectable in 
the nucleus (149, 203, 233). Even though an exact function of agnoprotein is still 
unknown, a role during virion assembly has been speculated (233). BKPyV 
agnoprotein has been found to be associated with lipid droplets (277), but the 
biological relevance of this is still unclear. Unlike BKPyV agnoprotein, JCPyV 
agnoprotein has been extensively studied. In the phosphorylated form, JCPyV 
agnoprotein primarily localizes to the cytoplasm, but in the dephosphorylated form, it 
translocates into the nucleus (212). JCPyV has been found to interact with LTag and 
thereby downregulate viral gene expression and DNA replication (240). JCPyV 
agnoprotein has also been suggested to function as a viroporin for the release of 
virions (269). 
microRNAs  
microRNAs (miRNAs) are small RNA molecules of approximately 22 
nucleotides that regulate gene expression (21). BKPyV and JCPyV encode a pre-
miRNA late in the infection that is processed into two functional 5p and 3p miRNAs 
homologous to SV40 miRNAs (256). BKPyV and JCPyV miRNAs are encoded by the 
early region but are transcribed by extension of the late transcript over the intergenic 
region into the early region. As a consequence, the miRNAs are perfectly 





downregulate LTag expression post transcriptionally in a small interfering RNA 
(siRNA)-like fashion by targeting and inducing cleavage of the early transcript (256, 
271). Aside from their autoregulatory role, polyomavirus miRNAs have effects on 
host gene regulation. The 3p miRNAs of BKPyV and JCPyV which are identical, 
target and downregulate ULBP3, a cellular stress-induced ligand for NKG2D receptor 
of Natural Killer cells and thus play an immune evasive role  (23). BKPyV encoded 
miRNAs have been implicated in viral latency or persistence (45). 
Viral replication 
The replication cycle of BKPyV has been characterized in primary human renal 
proximal tubular epithelial cells (RPTECs) and primary human urothelial cells (HUCs) 
(29, 178, 182).  One replication cycle of BKPyV in RPTECs takes 48-72 hours and 
approximately 72 hours in HUCs. The replication cycle of JCPyV has not been 
studied in detail, however, early protein LTag and late protein VP1 expression at 24 
and 48 hours postinfection (hpi), respectively in primary human fetal glial cells 







Figure 4. Schematic illustration of Polyomavirus replication. The numbers 
in the boxes indicate the order of the steps occurring during the replication. 
1TruncTag is only expressed by BKPyV and 2T’ags are only expressed by JCPyV 
(modified from (58)). 
 
The polyomavirus replication cycle (Figure 4) is described in detail below: 
Attachment: The efficient attachment to the host cell receptor is a prerequisite 
for a productive viral infection. For the attachment, the binding pocket of the BC loops 
of VP1 interacts with the specific cell surface receptor (80, 104). BKPyV uses α (2,3)-
linked sialic acid on N-linked glycoproteins or the gangliosides GD1b and GT1b as 
specific receptors (79, 183) while JCPyV uses terminal α (2,6)-linked sialic acid 
moiety present on lactoseries tetrasaccharide c (LSTc) as specific cellular receptors 
(164, 180, 209). In addition, the serotonergic receptor 5HT2AR has been suggested 





permissive HeLa cells (negative for 5HT2AR) by transfecting 5HT2AR (87). However, 
JCPyV infection was also found in 5HT2AR negative human brain microvascular 
endothelial cells, suggesting that it may serve as co-receptor or be dispensable for 
infection (51).  
Entry and uncoating: Post attachment, BKPyV  enters the host cells by 
caveolae mediated endocytosis while JCPyV enters the host cells by clathrin coated 
pit dependent endocytosis followed by caveolin-1-positive endosomes transport (201, 
221, 229). Intracellular trafficking of BKPyV and JCPyV is not well understood. It is 
suggested that once internalized, BKPyV and JCPyV are transported to the 
endoplasmic reticulum via the cytoskeleton where partial or complete 
uncoating/denaturation occurs and this partially denatured capsid enters into the 
nucleus (14, 80, 183). When the closely related SV40 virion is released into the 
cytosol from the endoplamic reticulum, the minor structural proteins VP2 and VP3 are 
exposed and promote the nuclear entry of SV40 DNA (207, 273). However, a study 
of JCPyV viral like particles (VLPs) showed that the nuclear localization signal of VP1 
was involved in its nuclear entry through the nuclear pore complex (228).  
 Early transcription and expression: Immediately after nuclear entry, 
complete uncoating of the virion occurs followed by the early gene transcription by 
cellular RNA polymerase II and translation that produces the early proteins. LTag 
mediates cell progression to the S phase by interacting with the key tumor 
suppressor proteins pRB and p53. In addition, SV40 LTag was shown to induce the 
DNA damage response via ataxia telangiectasia mutated (ATM) protein or ataxia 
telangiectasia and Rad3-related (ATR) protein pathway, and this pathway was found 
to be essential for efficient viral replication (reviewed in (125)). JCPyV-infected cells 





a result of the activation of ATM and ATR-mediated G2 checkpoint pathways and this 
seems to facilitate JCPyV replication (215). 
Genome replication: LTag is involved in the genome replication in at least two 
ways: first indirectly by stimulating the cell progression into the S phase, an important 
function since viral DNA replication is entirely dependent upon the cellular DNA 
synthetic machinery and second, LTag plays a direct role to initiate viral DNA 
replication. In more detail, LTag first undergoes oligomerization to generate a double 
hexamer and next, the Ori binding domain binds to the origin of replication of viral 
DNA via the consensus pentanucleotide G(A/G)GGC and unwinds the double 
stranded DNA in an ATP dependent pathway mediated by the ATPase domain (152, 
190). Immediately after unwinding, LTag recruits the pol α/primase complex, 
polymerase δ and cellular replication proteins to the origin of replication and initiates 
bi-directional replication of the viral DNA (reviewed in(58)).   
Late transcription and translation:  At the onset of viral DNA replication, LTag 
activates the late promoter and initiates late gene transcription and translation that 
produces the three capsid proteins VP1, VP2 and VP3; and the non-structural 
agnoprotein. In addition, during the late phase of viral life cycle, LTag binds to the 
NCCR and reduces the activity of the early promoter thus autoregulating early 
transcription via a negative feedback mechanism (69). 
Assembly: The specific sites of virion assembly are not well known yet (88). 
After the completion of the genome replication and the entry of the capsid proteins 
VP1, VP2 and VP3 to the nucleus, the packaging of DNA with cellular histones 
(minichromosome) is followed by polyomerization of capsid proteins on the 





Release: The mechanism for progeny release is not well known. It is thought 
that over expression of viral proteins or the production of large amounts of progeny 
cause instability of the cell membrane leading to cell lysis. For SV40, a late protein 
denoted VP4 has been suggested to be involved in this process (64). There is also 

















BK and JC polyomavirus infection, diseases and treatment options 
Primary infection, latency and reactivation 
BKPyV and JCPyV which are transmitted independently of each other, infect  a 
large proportion of the population without any specific signs or symptoms and then 
establish a latent infection in the renourinary tract (52). Interestingly, the primary 
infection of BKPyV commonly occurs during early childhood while that of JCPyV 
usually occurs during late childhood and adulthood (85, 162, 266). In a large study of 
1501 blood donors and 721 children under 21 years of age, almost 80% of the 10 
year old children and 87% of individuals between 21 to 50 years of age were 
seropositive for BKPyV but from that age, the seropositive was slowly declining 
(157). In the same study, JCPyV seropositive was found in about 20% of 10 year old 
children and was found to be continuously increasing with increasing age to reach 
the maximum of 51% by the age of 70 years. Although the exact percentages found 
in this study especially for JCPyV differ from the results found in other studies (85) 
possibly due to different methodology and population investigated, the trend is 
similar. Of note, in a study of HIV-1 infected patients, a JCPyV seropositivity of 90% 
was detected which suggested that risk factors associated with HIV-1 affect JCPyV 
transmission (132). 
After the primary infection, sporadic reactivation causes asymptomatic urinary 
shedding of low levels BKPyV and/or JCPyV. In one study of 400 healthy blood 
donors from Switzerland, BKPyV or JCPyV DNA was found in the urine samples of 7 
and 19% of the donors, respectively (85). However, in a smaller study of 20 female 
students where daily urine samples were examined over a period of two months, 
BKPyV DNA was found in urine samples from 55% of the students and JCPyV DNA 





Even though the source of infection and mode of transmission is not completely 
resolved for either BKPyV or JCPyV, the fecal-oral route has been suggested based 
on the asymptomatic shedding of viruses in urine,  the detection of the viral DNA in 
stool and saliva of healthy adults and in sewage (34, 85, 146, 281). Other suggested 
routes of transmission include transplacental transmission, transfusion of blood 
products, semen, and organ transplantation, particularly kidney allografts (reviewed 
in (135)).   
In individuals with impaired immune function due to disease, pregnancy or 
treatment, reactivation of BKPyV in epithelial cells of the renourinary tract is more 
frequent and replication occurs at high level. This can lead to diseases, especially in 
KT and allogenic hematopoietic stem cell transplant (HSCT) patients (reviewed in 
(62)). Interestingly, shedding of JCPyV in urine is not connected to altered immune 
function but only a marker for ongoing replication in the urinary tract (132). However, 
JCPyV associated disease PML is almost exclusively affecting immunocompromised 
patients. 
Polyomavirus-associated nephropathy  
Although the first report describing a disease resembling polyomavirus-
associated nephropathy (PyVAN) came in 1978, it was not before the late 1990s that 
PyVAN emerged, possibly due to the introduction of new and more effective 
immunosuppressive drugs such as mycophenolate mofetil and tracolimus (126).  
PyVAN is now recognized as the major viral complication in KT patients (129).  
Approximately 1-10% of all KT patients are affected by PyVAN within the first year 
after the transplantation (129). Although BKPyV is the major cause of PyVAN, JCPyV 
has been found to cause a few cases but this accounts for less than 1% of total 





The pathogenesis of PyVAN involves high-level BKPyV replication in epithelial 
cells lining the kidney tubules leading to necrosis, kidney dysfunction and 
subsequently allograft loss. During PyVAN, BKPyV with rearranged NCCRs emerge 
and they have an increased viral replication and give increase cytopathology 
compared to the archetype strain (111). Although immunosuppression is a major risk 
factor for PyVAN, the almost exclusively occurrence in KT patients suggests that 
factors specific to these patients are of importance (134). They include recipient 
determinants such as older age, male gender and negative BKPyV serostatus 
especially in pediatric recipients, donor determinants such as HLA mismatch, 
deceased donation, BKPyV load in the graft and female gender, graft determinants 
such as ureteric stents and modulating factors after transplantation like acute 
rejection or anti-rejection treatment.   
The diagnosis of PyVAN is stratified into three categories: possible, 
presumptive and proven PyVAN based on quantitative PCR, cytology of urine and 
histopathological findings (134). In possible PyVAN, urine BKPyV DNA loads are 
high (>107 Genome Equivalents (GEq)/ml), decoy cells are present but plasma is 
BKPyV negative. In presumptive PyVAN, plasma is BKPyV DNA positive (>104 
GEq/ml) in addition to high urine BKPyV DNA loads or decoy cells. In proven PyVAN, 
histopathological findings are present in addition to positive plasma and high urine 
BKPyV DNA loads (134). A proven PyVAN is further categorized into three different 
histopathological stages which indicate the severity of PyVAN. Stage A is 
characterized by mild viral cytopathic changes  with minimal interstitial inflammation 
and fibrosis, and tubular atrophy and has a <10% risk of graft loss; Stage B is 
characterized by moderate to significant viral cytopathic changes and interstitial 





75% risk of graft loss; and stage C is characterized with variable viral cytopathic 
changes and interstitial inflammation with extensive tubular atrophy and interstitial 
fibrosis and has >80% risk of graft loss (76, 134).  
Of note, the focal nature of the infection can lead to false negativity in biopsy 
samples particularly in early stages of PyVAN (reviewed in (77)). To avoid this, a 
minimum of two core biopsies should be taken, preferentially containing medullary 
tissues (134). Urine cytology has been used as a screening test to detect epithelial 
cells bearing BKPyV inclusion, often called decoy cells. However, today, the most 
important tool for screening patients for PyVAN is quantitative PCR of urine and 
plasma. It is recommended to screen for BKPyV in urine or plasma every three 
months for the first two years after transplantation. More than 107 and 104 GEq/ml of 
BKPyV DNA in urine and plasma, respectively, indicate the development of PyVAN 
(131). The absence of viruria practically rules out PyVAN (reviewed in (77)). Early 
diagnosis and early treatment of PyVAN has increased the graft survival (128).  
Polyomavirus-associated hemorrhagic cystitis  
Hemorrhagic cystitis is defined as a hemorrhagic inflammation of the urinary 
bladder mucosa leading to painful hematuria, severe bladder hemorrhage, and 
possibly to clot-related urinary retention and kidney failure. Hemorrhagic cystitis is 
categorized into an early onset hemorrhagic cystitis that occurs in HSCT patients 
within days following chemotherapy and irradiation; and a late onset hemorrhagic 
cystitis which is also called infectious hemorrhagic cystitis, occurring about 50 days 
after HSCT. The late hemorrhagic cystitis is associated with reactivation of urotropic 
viruses such as BKPyV, adenovirus and cytomegalovirus (173). A hallmark of 
polyomavirus-associated hemorrhagic cystitis (PyVHC) is high-level BKPyV 





PyVHC is not fully understood, the following sequence of events has been suggested 
(20, 31). First, urotoxicity of the conditioning protocol causes subclinically damage to 
the urothelium. Next, during the aplastic phase, immunologically uncontrolled BKPyV 
replication is occurring leading to urothelial denudation, urine leakage, and 
hematuria. Finally, upon engraftment a stronger inflammation and cytopathic damage 
is seen (reviewed in (130)). The incidence of PyVHC after allogeneic HSCT is 5-15% 
(130). The risk factors associated with PyVHC are allogeneic versus autologous 
HSCT, myeloablative conditioning, a transplant from an unrelated donor, cord blood 
transplantation and BKPyV seropositive prior to transplantation (reviewed by (108)). 
The diagnosis of PyVHC requires the triad of cystitis, hematuria and high-level 
BKPyV replication with urine BKPyV DNA load of >107 GEq/ml (130). In a study on 
children, BKPyV viremia preceded PyVHC (168) and in a study on adults viremia was 
correlated with the severity of the disease (108). 
Progressive multifocal leukoencephalopathy  
PML is usually a fatal demyelinating disease of the central nervous system 
(CNS) in immunosuppressed individuals caused by the cytopathic replication of 
JCPyV in myelin-producing oligodendrocytes. PML was first described in 1958 in a 
patient with chronic lymphocytic leukemia and Hodgkin’s lymphoma (16). It was a 
rare complication of immunocompromised particularly neoplastic patients until the 
pandemic of HIV started. During the 1980s, about 5% of HIV positive patients 
developed PML and this patient group still constitutes approximately 80% of all PML 
cases (27). Recently, an increased incidence of PML was reported in patients with 
autoimmune diseases who underwent immunomodulatory therapies. The incidence 
rate of PML was up to 11.1 cases per 1000 multiple sclerosis patients treated with 





into the brain, if the patient was JCPyV seropositive, had taken immunosuppressants 
before the initiation of natalizumab and had received 25 to 48 months of natalizumab 
treatment (33). An incidence of 1 in 500 was seen in psoriasis patients treated with 
efalizumab, a monoclonal antibody that prevents T and B lymphocytes migration from 
blood vessels into the tissues (91). PML also occurs in 1 of 2500 rheumatoid arthritis 
patients treated with rituximab, a monoclonal antibody that depletes B cells from the 
peripheral circulation and cerebrospinal fluid (CSF) (50, 55). Similarly, though less 
frequently, PML has been reported in patients with impaired immune functions for 
other reasons such as solid organ transplant (SOT) and allogenic HSCT, as well as 
idiopathic CD4 lymphocytopenia (10, 27, 68, 133) and sometimes in individuals with 
minimal or occult immunosuppression  (106, 113, 205). 
Recently, three different but not mutually exclusive hypothesis were postulated 
for PML pathogenesis (132). i) After primary infection, JCPyV reaches and remains 
latent in the CNS. When the JCPyV specific T cell level decreases in the CNS, 
JCPyV reactivates and causes cytolytic replication in the oligodendrocytes with 
ensuing progression to PML. ii) After primary infection, JCPyV persists in other cells 
of the body, i.e. lymphocytes or hematopoietic progenitor cells and reactivates when 
JCPyV specific T cell level decreases. Then, via occult viremia, JCPyV reaches the 
CNS causing cytolytic replication leading to PML. iii)  After primary infection, JCPyV 
persists in lymphocytes or bone marrow progenitor cells and these latently infected 
cells migrate to the CNS where the virus reactivates causing cytolytic replication 
under the condition of decrease or absence of JCPyV specific T cells. 
The diagnosis of PML is very challenging and requires recognition of the clinical 
presentation, backed up by compatible findings in magnetic resonance imaging of the 





neurological deficits of mostly motor, cognitive and visual functions (132). 
Demonstration of JCPyV DNA in CSF is confirmatory but frequently negative in the 
early stages of disease. Not uncommonly, repeated CSF testing and/or brain biopsy 
is necessary. As such, the diagnosis demands a high degree of clinical suspicion and 
perseverance. Detection of JCPyV DNA in the plasma is not helpful as many PML 
patients are not viremic (91) and plasma JCPyV DNA has not been accepted as a 
marker of PML disease (10). 
Since diagnosing PML can be difficult, the three different terms are used: i) 
Possible PML which defines those patients who are at high risk with the relevant 
clinical and radiological signs but where JCPyV DNA is undetectable in CSF by PCR. 
ii) Probable PML defines patients with PCR positive JCPyV DNA in CSF and have 
multifocal neurological deficits and corresponding radiological findings. This is also 
called virologically or laboratory confirmed PML. iii) In proven PML, also referred to 
as histologically proven PML, a brain biopsy of the affected area shows 
demyelination with viral cytopathic alterations surrounded by macrophages and 
atypical astrocytes. JCPyV involvement is demonstrated by either positive 
immunohistochemistry for LTag or VP1 positive in situ hybridization (reviewed in 
(132)). 
Other diseases associated with BKPyV and JCPyV 
BKPyV-associated ureteric stenosis is reported in 2-6 % of KT patients 
(reviewed by (280)). In fact, the first BKPyV isolation was made in a KT patient 
suffering from ureteric stenosis (100). The pathogenesis of ureteric stenosis is still 
not completely resolved. It is suggested that high doses of  steroids in the KT 
patients may permit high-level BKPyV replication in the urothelium and underlying 





Apparently, ureteric stenosis is now less frequently reported possibly due to a decline 
in the use of ureteral stents (42, 129). Of note, irreversible BKPyV-associated 
ureteric stenosis has not been reported in non-KT patients (280). The treatment 
options include percutaneous nephrostomy and concurrent reduction of 
immunosuppression (280). 
BKPyV-associated diseases of the CNS have been reported. BKPyV was 
found to be associated with meningoencephalitis in two HIV positive patients and an 
SOT patient; and with PML-like disease in a KT patient (41, 114, 136, 278). Recently, 
a case of BKPyV-associated PML was reported in an immunocompromised patient 
(65).  
The potential role of BKPyV and JCPyV in cancer has been demonstrated 
by the capability of their early T antigen proteins to induce transformation of cells in 
vitro and cause tumors in laboratory animals (reviewed in (284)). BKPyV or JCPyV 
DNA/proteins have been found in different human neoplasms (reviewed in (62, 132, 
234, 284)). In 2012, WHO international agency for cancer Research Monograph 
Working Group classified BKPyV and JCPyV as possibly carcinogenic to humans 
(group 2B) based on the inadequate evidence in humans and sufficient evidence in 
experimental animals (39). 
JCPyV-associated granule cell neuronopathy was described in HIV positive 
patients, in a natalizumab treated multiple sclerosis patient and in a rituximab treated 
non-Hodgkin lymphoma patient (63, 78, 165, 246). JCPyV-associated granule cell 
neuronopathy is caused by the cytopathic replication of JCPyV in granule cell 





JCPyV-associated encephalopathy  is caused by the cytopathic replication of  
JCPyV in cortical pyramidal neurons and was reported in a HIV negative lung cancer 
patient (289).  
JCPyV-associated meningitis was first described when JCPyV DNA was 
detected by PCR in the CSF of two immunocompetent patients with suspected 
meningitis (25). Recently, a definitive case of JCPyV-associated meningitis was 
reported in an immunocompetent individual (5). The CSF was JCPyV DNA positive 
and immunohistochemistry staining of brain tissue showed significant JCPyV 
infection of the leptomeningeal cells of the pia mater surrounding the cerebrum and 
cerebellum.  
Treatment of polyomavirus-associated diseases  
There is still no effective anti-BKPyV or anti-JCPyV drug available. One of the 
reasons for this is that these small viruses encode only few proteins and therefore 
have only few targets for direct acting agents.  
For KT patients with PyVAN, the best available treatment option is to regain 
immune function by cautiously reducing or changing the immunosuppressive drugs. If 
this is performed at an early stage of the disease, this may control the viral 
replication, clear BKPyV viremia and stop the progression of PyVAN (109, 119, 245). 
Unfortunately, this treatment option at the same time increases the risk of acute 
rejection (151). Even more, the restoration of immune function is not always possible 
or enough to control the viral replication, therefore, drugs like cidofovir, leflunomide, 
and fluoroquinolones and intravenous immunoglobulin have been used as adjunctive 
therapy especially in a combination with the reduction of immunosuppression 
(reviewed in (151)). Cidofovir is a nucleoside analogue that is licensed to treat 





Cidofovir effectively reduced BKPyV replication in primary RPTECs, but gave 
considerable cytostatic effects (29) and is also known to be nephrotoxic and can give 
irreversible acute kidney failure (137, 216). Leflunomide is an inhibitor of de novo 
pyrimidine synthesis and is licensed for the treatment of rheumatoid arthritis (234). 
Leflunomide also inhibits BKPyV replication in primary RPTECs but with significant 
cytostatic effects (30) and has been reported to give anemia, liver damage, lung 
toxicity and thrombotic microangiopathy (19, 170, 237). Although some case reports 
showed favorable outcome of PyVAN after treatment with either cidofovir or 
leflunomide, a systemic review of the studies published until 2009 showed that there 
was no clear benefit of these drugs over the reduction of immunosuppression alone 
(151). The fluoroquinolones are synthetic broad spectrum antibacterial agents which 
inhibit the two bacterial enzymes topoisomerase II and IV (159). It has been 
speculated that fluoroquinolones can inhibit the helicase activity of BKPyV LTag as 
described for SV40 LTag (8, 259). The fluoroquinolones ofloxacin and levofloxacin 
were found to inhibit BKPyV replication in primary RPTECS (259). The mechanism 
for this could be by the inhibition of LTag helicase activity, but since the replication of 
cellular DNA was reduced, the inhibition of cellular topoisomerase II was also 
suggested. Fluoroquinolones have been investigated in some non-randomized 
studies as prophylaxis or treatment of BKPyV infection after KT or HSCT with 
favorable and unfavorable outcomes (97, 167, 172, 276, 286). At the moment, there 
is one ongoing phase 4 study where ciprofloxacin is given as prophylactic the first 6 
months after the KT (Clinical Trials.gov NCT01789203). 
Intravenous immunoglobulin contains pooled IgG from the plasma of 
approximately 1000 blood donors (226, 234) and contain neutralizing antibodies 





immunoglobulin has been used as treatment of BKPyV infection with variable 
success (255, 283). But, in two patients, a significant increase of urine and plasma 
BKPyV load was seen after intravenous immunoglobulin administration and the 
patients progressed to PyVAN (38, 186).  The fact that some KT patients with high 
titers of BKPyV IgG  developed PyVAN raises a question about the benefit of this 
treatment (35). 
While PyVAN partly results from reduced immune surveillance, PyVHC is partly 
caused by recovery of the cellular immune response upon engraftment (62). The 
treatment of PyVHC is, therefore, mainly supportive involving symptomatic analgesia, 
hyperhydration, diuresis and continuous bladder irrigation to prevent clot formation 
and urinary tract obstruction; and  substitution of platelets and erythrocytes (130).  As 
for PyVAN, adjunctive prophylaxis or treatment with cidofovir or fluoroquinolones has 
been used without any documented benefit (234). Moreover, hyperbaric oxygen 
either alone or in combination with intravesicular cidofovir has been successfully 
used to treat PyVHC (95, 120, 243). The hyperbaric oxygen is believed to stimulate 
the repair of mucosa in the urinary bladder (95).  
So far the only efficient treatment of PML is to regain immune function. In 
HIV/AIDS patients, this can be achieved by the start of HAART/cART treatment, in 
SOT patients by the reduction of the immunosuppressive therapy and in patients with 
autoimmune disease by removing the immmunomodulatory therapies. However, the 
rapid increase in immune function leads to immune-reconstitution inflammatory 
syndrome in 40% of all PML patients with mortality rate upto 53% (115). Many broad 
spectrum nucleoside analogues such as cytosine arabinoside, adenosine 
arabinoside, azidothymidine, acyclovir and cidofovir have been used to inhibit JCPyV 





an antimalarial drug, was found to inhibit JCPyV replication in vitro (43) and has been 
used successfully to treat some PML patients (3, 26, 160, 194, 206, 261, 291) while it 
was unsuccessful for others (56, 113, 163, 200, 241). In a clinical trial comparing 
CSF JCPyV DNA load in PML patients receiving standard care with those who 

















Artemisinin, and its derivatives artesunate (Figure 5), artether, artemether and 
the active metabolite dihydroartemisinin (Figure 5) are well known antimalarial drugs 
with high tolerability and a good safety record (61). In 2005, World Health 
Organization officially recommended artemisinin and its derivatives for the treatment 
of malaria particularly in a combination with other antimalarial drugs to avoid 
resistance development. Additionally, artesunate was found to have antiviral, 
antiparasitic, antifungal, anti-inflammatory and anti-allergic properties both in vitro 
and in vivo (reviewed in (138)). 
 
 
Figure 5. Schematic illustration of chemical structure of artesunate and its active 
metabolite dihydroartemisinin showing endoperoxide bridge inside the ring. 
Tu and his colleagues at the China Academy of Chinese Medical Sciences were 
searching for an active compound against malaria and in 1972, they extracted 
artemisinin from the Chinese medicinal plant Artemisia annua L. and found this to be 





parasites (274). Artemisinin is a sesquiterpene lactone consisting of a distinctive 
endoperoxide bridge which is considered to be responsible for its antimalarial activity. 
Since artemisinin was poorly soluble in water or oil and could not be administered to 
the patients intravenously, several derivatives from artemisinin have been developed 
such as the oil soluble artemether and artether as well as the water soluble 
artesunate. In fact, these derivatives were developed from dihydroartemisinin which 
was produced by reducing the lactone group of artemisinin to a lactole (hemiacetal 
function) by sodium borohydride (reviewed in (61, 171)). Of note, dihydroartemisinin 
was the first derivative made, but it was as poorly soluble in water and oil as was its 
parental drug (12, 174) and later it was recognized as the active metabolite of 
artesunate and other artemisinin derivatives.   
Artesunate is a succinate esterified dihydroartemisinin (171) and it is the only 
derivative that can be given to patients orally, intravenously, intramuscularly and 
rectally. It has remarkable activity against plasmodium falciparum and plasmodium 
vivax and is highly effective in the treatment of severe malaria (83). In vivo, 
artesunate is rapidly and extensively converted through esterase-catalyzed 
hydrolysis to dihydroartemisinin and artesunate is therefore considered a prodrug. 
Interestingly, during in vitro testing against plasmodium falciparum, both artesunate 
and dihydroartemisinin was found to be equally potent and significantly more active 
(3-5 fold) and also toxic than the other artemisinin derivatives (175, 177). During 
elimination, dihydroartemisinin is resolublized and inactivated by glucuronidation in 
the liver followed by excretion in the urine (102, 143). 
A meta-analysis of 16 randomised malaria treatment trials conducted for 
artesunate in combination with other drugs (chloroquine or amodiaquine or 





of artesunate (4). Because of its high safety profile and tolerability, the potency of 
artesunate in other areas has also been extensively studied.  As a result, artesunate 
and dihydroartemisinin were found to inhibit the proliferation of a wide variety of 
cancer cells in vitro and to reduce tumor size in animal models (review in (138)).  
Artesunate has been used to treat cancer patients and some case studies showed 
that artesunate reduced the tumor growth of laryngeal squamous cell carcinoma and 
metastatic uveal melanoma and increased the survival rates of the patients (28, 263). 
In a randomized control trial of 120 advanced non-small cell lung cancer, artesunate 
combined with a chemotherapy regimen of vinorelbine and cisplatin was found to 
increase the short term survival and prolong the cancer progression time (the full 
article is in Chinese) (293). 
Mechanism for antimalarial and anticancer activity  
The mechanism for the antimalarial and anticancer activity of artesunate and 
other artemisinins is not understood yet (71, 74). However, it is believed that the 
endoperoxide bridge is responsible for both activities (reviewed in (71, 93, 138)). The 
endoperoxide bridge undergoes hydrolysis and produces toxic radicals such as, for 
example, reactive oxygen species (ROS) or a carbon centered radical, a highly 
potent alkylating agent. Interestingly, the hydrolysis of the endoperoxide bridge is 
greatly enhanced by the presence of free iron (82). The suggested antimalarial 
mechanism is that these toxic radicals interfere with the heme detoxification pathway, 
inducing alkylation of the plasmodium falciparum translationally controlled tumor 
protein (PfTCTP) encoded by the pftctp gene and other proteins. This may inhibit the 
sarco-endoplasmic reticulum calcium dependent ATPase (SERCA) protein encoded 
by the PfATPase6 gene, or interfere with plasmodium mitochondrial functions 





oxidative cellular damage and as a result, a wide variety of effects have been found, 
including cell cycle arrest, induction of apoptosis, alteration of hormone responsive 
properties and/or inhibition of angiogenesis in a variety of human cancer cells 
(reviewed in (93, 138)). Since most of the cancer cells are enriched with iron 
compared to normal cells (reviewed in (153)), they are more prone to be affected. 
Antiviral activities 
The first hint of antiviral properties of artemisinin against influenza A virus was 
already provided by Chinese Scientists in the 1980s (227).  In 2002, Efferth and his 
colleagues observed antiviral properties of artesunate while investigating its 
antiproliferative activities in cell culture (83). Artesunate was found to inhibit the 
replication of a wide variety of human viruses (Figure 6 and Table 2). The extensive 
studies on HCMV in vitro demonstrated that artesunate is equally effective against 
both ganciclovir sensitive and resistant strains (54, 83). Since activation of HCMV 
replication is differently regulated in different types of cells, the efficacy of artesunate 
against HCMV was tested in a wide variety of human cells including astrocytoma, 
foreskin- and lung-fibroblast cells and the results showed a strong inhibitory effect in 
all cells tested (54, 83, 94, 155, 195, 239). However, there was some variation in the 
half maximal effective concentration (EC50) (Table 2) and it was therefore suggested 






Figure 6. Schematic overview of different viruses effected by artesunate (modified 
from (84)). 
 
Dihydroartemisinin has also been investigated for its anti-cytomegalovirus 
activities in vitro but the studies showed that it was less effective compared to 
artesunate (54, 94). However, the results were not straight forward. At low dose of 
about 1.6 microMolar (µM), dihydroartemisinin and artesunate inhibited HCMV 
replication to the same extent, but at higher doses, dihydroartemisinin showed less 
effect than at a lower dose and was significantly less effective than artesunate (54).  
In another in vitro study of HCMV replication, artesunate was found to be superior to 
dihydroartemisinin when given as a single dose but, after fractional doses, 
dihydroartemisinin was equal to or even more effective than artesunate (94). This 
could perhaps be explained by the poor stability of  dihydroartemisinin compared to 






Table 2. The half maximal effective concentration (EC50) of artesunate for different 




Host cell References 
HCMV AD169- Laboratory strain 5.8±0.4 HFF (83) 
HCMV AD169- GCV resistant 6.9±0.2 HFF (83) 
HCMV AD169 3.7±0.1 HFF (155) 
HCMV AD169 3.0±1.0 MRC-5 (247) 
HCMV AD169 2.22±0.48 U373MG (247) 
HCMV AD169 4.31±0.17 HFF (54) 
HCMV AD169 3.46±1.14 MRC-5 (94) 
HCMV wt 3.26±1.36 HEL (54) 
HCMV wt 2.76±0.58 HFF (54) 
EBV B95-8 7.21±2.25 Raji (195) 
EBV B95-8 6.4±2.7 Raji (17) 
EBV B95-8 3.1±0.9 293T (17) 
HCMV maribavir resistant 4.01±0.51 HEL (54) 
HCMV maribavir resistant 2.96±0.65 HFF (54) 
HCMV Ganciclovir resistant 4.73±1.4 HEL (54) 
HCMV Ganciclovir resistant 3.72±1.1 HFF (54) 
HCMV Ganciclovir/ Cidofovir resistant 4.8±0.3 HEL (54) 
HCMV Ganciclovir/ Cidofovir resistant 2.9±0.6 HFF (54) 
HCMV Foscarnet resistant 4.5±0.4 HEL (54) 
HCMV Foscarnet resistant 3.2±0.5 HFF (54) 
HCMV Ganciclovir/ Foscarnet/Cidofovir 
resistant 
4.62±1.91 HEL (54) 
HCMV Ganciclovir/ Foscarnet/Cidofovir 
resistant 
2.62±0.75 HFF (54) 
HCMV clinical isolate 2.16±1.08 MRC-5 (94) 
HHV-6A U1102 3.80±1.06 HSB-2 (195) 
HBV (HBsAg and HBV DNA) 2.3  &  0.5 HepG2 2.2.15 (235) 
BK polyomavirus 4.2 RPTECs (260) 
MRC-5:   Human lung fibroblasts 
HFF:        Human foreskin fibroblasts 
Raji:         Human B lymphoblast 
U373MG:    Human astrocytes 
HEL:          Human embryonic lung 
HSB-2:        Human T lymphoblast 
RPTECs:  Human primary renal proximal tubular epithelial cells 
HepG2 2.2.15:Human hepatoma cells transfected with HBV DNA 






As with the antimalarial and anticancer activities of artesunate, the molecular 
mechanism for the antiviral effect of artesunate is not yet completely understood. 
Artesunate inhibits the expression of HCMV immediate early genes and the viral 
DNA replication (17, 83). This inhibition is suggested to be connected to the 
interference of artesunate with the central regulatory pathways of HCMV infected 
cells. By inhibiting NF-kB or Sp1 dependent activation pathways, artesunate 
interferes with critical metabolic requirements for HCMV replication (84). Again the 
importance of endoperoxide in the inhibition of HCMV by artesunate is further 
underscored by the lack of inhibition of HCMV by an artemisinin deoxy dimer lacking 
endoperoxide (123). Of note, as found for the antimalarial and anticancer activities, 
iron also increased the activity of artestunate against HCMV in vitro (155). 
Due to its strong antiviral activity against a variety of herpes virus in cell culture, 
artesunate has been used to treat herpes virus diseases. To our knowledge, a total 
of 14 patients, 9 HSCT, 4 SOT and 1 pediatric patient with heart disease, have been 
treated with oral or intravenous artesunate for viral infections and of these, 7 patients 
cleared with the viral infection (105, 116, 169, 254, 258, 287). Two HSCT and two 
SOT (1 KT and 1 lung transplant) patients with multidrug resistant HCMV infection 
were orally treated with artesunate at a dose of 100-200 mg/day; and favorable 
clinical and virological response was reported at 10-30 days for HSCT and 1-3 
months for SOT patients after the treatment started (105). The treatment was 
continued for 1 to 7 months. Of note, one of the HSCT patients received foscarnet in 
combination with artesunate. In addition, one HSCT patient with multidrug resistant 
herpes simplex virus-2 (HSV-2) infection was successfully treated with oral 
artesunate 100 mg per day for 30 days (254). This patient had two more episodes of 





patient with severe heart failure was successfully treated for human herpes virus-6B 
(HHV-6B) infection (116). In this patient, artesunate was given intravenously at a 
dose of 5 mg/kg/day for 10 days and then continued orally with 2X5 mg/kg/day for 10 
more days. On other hand, artesunate failed to cure valganciclovir resistant HCMV 
infection of KT patients after a 30 day treatment (169). In a clinical trial, pre-emptive 
treatment for HCMV infection in 5 HSCT patients was tested.  Oral artesunate at a 
dose of 2X200 mg per day for one day, followed by 100 mg/day for 28 days was 
given, but this was successful in one of the 5 patients (www.clinicaltrials.gov 
NTC00284687) (287).  For some of the unsuccessfully treated patients, a reduction 
of the viral load was seen (105), which might indicate some effect. To summarize the 
results of these studies, by curing 7 of 14 patients, artesunate had a success rate of 
50%. As part of two randomized malaria treatment trials, artesunate at a dose of 4 
mg/kg/day was given to children for 3 days, and this did not reduce HCMV infection 
when investigated by qPCR of dried blood samples collected (98). However, in this 











Aims of the study 
The aim of this thesis was to explore the possible future use of the antimalarial 
drug artesunate as a treatment for PyVAN, PyVHC and PML by investigating the 
antiviral effect on BKPyV and JCPyV replication in authentic cell culture models.  
Paper I 
 PyVAN is caused by high-level lytic replication of BKPyV in kidney tubular 
epithelial cells in the graft of KT patients.  The aim of this study was to perform a 
detailed investigation of the effects of artesunate on BKPyV replication in primary 
human RPTECs, the target cells for BKPyV in PyVAN. 
Paper II 
High-level replication of BKPyV in urothelial cells is a common feature of 
PyVAN and PyVHC. The aim of this study was to characterize the replication of 
BKPyV in primary HUCs from bladder and compare it to BKPyV replication in 
RPTECs.  
Paper III 
PyVHC pathogenesis involves high-level replication of BKPyV in bladder 
urothelial cells. The aim of this study was to investigate the effect of artesunate on 
BKPyV replication in primary HUCs, previously characterized in paper II. 
Paper IV 
PML is caused by high-level lytic replication of JCPyV in oligodendrocytes. 
Since primary human oligodendrocytes are difficult to obtain and propagate, the aim 
of this study was to first compare the permissivity of COS-7, HEK 293TT, SVG-A and 
M03.13 cell lines for JCPyV replication; and second to investigate the effect of 





Summary of the papers 
Paper I 
Artesunate, a widely used antimalarial drug, has shown antiviral activity 
against a wide variety of herpes viruses (Table 2). Here, we investigated the effect of 
artesunate on BKPyV replication in RPTECs, the major target cells in PyVAN. 
Artesunate inhibited BKPyV replication in a concentration-dependent manner with a 
50% effective concentration (EC50) of 4.2 µM. Artesunate at 10 µM reduced the 
extracellular BKV load by 65% at 72 hpi. The inhibition was seen on early LT ag and 
late VP1 mRNA and protein expression; and on BKPyV DNA replication. Importantly, 
the proliferation of RPTECs was also inhibited in a concentration-dependent manner. 
At 72 hpi, artesunate at 10 µM reduced cellular DNA replication by 68% and total 
metabolic activity by 47%; these reductions were connected to cytostatic but not a 
cytotoxic effect and the cells were arrested in G0 or G2 phase of cell cycle. Both the 
antiproliferative and antiviral effects of artesunate at 10 µM were reversible. In 
conclusion, artesunate inhibits BKPyV replication in RPTECs by inhibiting BKPyV 
gene expression and genome replication. The antiviral mechanism appears to be 
closely connected to cytostatic effects on host cells, underscoring the dependence of 
BKPyV on host cell proliferative functions. 
Paper II 
  High-level BKPyV replication in HUCs is a hallmark of PyVHC and PyVAN.   
We characterized BKPyV replication in HUCs and compared it to the replication in 
RPTECs. HUCs were easily infected, as shown by expression of LTag, VP1-3, and 
agnoprotein, and intranuclear virion production. Compared to RPTECs, progeny 
release was delayed by ≥ 24 hours. BKPyV-infected HUCs rounded up like ‘‘decoy 





RPTECs is significantly different and the data support the notion that PyVHC 
pathogenesis is not solely due to BKPyV replication, but likely requires urotoxic and 
immunological cofactors. 
Paper III 
Here, we investigated the effect of artesunate on BKPyV replication in HUCs, 
the major target cells in PyVHC but is also targeted in PyVAN. Artesunate inhibited 
BKPyV replication in HUCs with an EC50 of 6.2 µM. No inhibition was seen on 
BKPyV DNA replication. Artesunate inhibited cell proliferation and concentrations 
from 10 µM resulted in a slightly reduced number of viable cells at 72 hpi. Of note, a 
single dose of 20 µM produced stronger effect than multiple doses of 10 µM. In 
conclusion, artesunate affects late steps in the BKPyV replication cycle in HUCs and 
this is closely linked to significant cytostatic effects. 
Paper IV 
  High-level lytic replication of JCPyV in oligodendrocytes causes PML, an often 
fatal disease of brain, mainly affecting immunosuppressed individuals. Here, we 
investigated the effect of artesunate on JCPyV replication in COS-7 cells. The 
permissivity for JCPyV MAD-4 was first compared for HEK 293TT, SVG-A and 
M03.13 cell lines; and COS-7 was selected for the study. Artesunate caused a 
concentration-dependent decrease in extracellular JCPyV DNA load with an EC50 of 
3.0 µM at 96 hpi. This effect correlated with an inhibition of the expression of VP1, 
production and release of infectious viral progeny. For concentrations below 20 µM, a 
transient reduction in DNA replication and cell proliferation was seen, while for higher 
concentrations some cytotoxicity was detected. Interestingly, the JCPyV-infected 
cells were more sensitive to the cytostatic effect of the drug than the mock-infected 





cellular DNA replication. In conclusion, artesunate inhibits JCPyV replication in COS-
7 cells at µM concentrations and the inhibition probably reflects an effect on cellular 





















General discussion  
High-level BKPyV replication in kidney tubular epithelial cells and bladder 
urothelial cells causes PyVAN in KT patients and PyVHC in allogeneic HSCT patients, 
while lytic replication of JCPyV in oligodendrocytes in the context of 
immunosuppresion causes PML. These serious diseases remain significant 
challenges since no effective and safe antiviral treatment is available (132, 234). 
Currently, the restoration of virus-specific immune functions in patients with PyVAN or 
HIV positive PML patients is the only way to control and reverse these replicative 
diseases. However, the recovery of immune functions has significant clinical 
limitations, because of undesired side effects such as transplant rejection and/or 
immune- reconstitution inflammatory syndrome in patients with PyVAN and PML, 
respectively. Moreover, this strategy may not be rapidly available in some transplant 
patients and almost impossible to achieve in a timely fashion in cancer patients. In 
PyVHC patients, the inflammatory response following the recovery of the cellular 
immune response may actually be part of the pathogenesis, although further studies 
are needed to identify the key mechanisms (62). Thus, antiviral therapies are 
expected to play a significant role in all patients affected by BKPyV and JCPyV 
diseases to either extend the time window for immune reconstitution or to primarily 
block viral replicative damage. In some studies, certain drugs have been used with 
only limited or no evidence of antiviral efficacy for BKPyV and JCPyV replication, but 
sometimes severe side effects instead (19, 137, 170, 216, 237). Therefore, the search 
for safe drugs with antiviral properties against BKPyV and JCPyV is clearly warranted 
today. Given the long process of drug development and licensing, it is of interest to 





convincing antiviral properties. This could dramatically shorten the time to clinical use 
and even provide some experience in compassionate or off-label use.  
The aim of this PhD project was to investigate the effect of the antimalarial drug 
artesunate on BKPyV and JCPyV replication in cell culture. Artesunate caught our 
attention since this drug has been safely used by millions of people with severe 
malaria (73), the drug has shown broad antiviral properties in vitro (Table 2) (17, 83, 
84, 195, 235, 236) and has been reported to be successfully used in patients with 
multiresistant HCMV (105, 258), HSV-2  (254) and HHV-6B infection (116).  In our 
work, we show for the first time that artesunate inhibits BKPyV replication in RPTECs 
and in HUCs, in a concentration-dependent manner (Paper I and III). The inhibition of 
viral replication in vitro is closely connected to inhibition of host cell proliferation. 
However, for RPTECs, this inhibitory effect was only transient. Although the precise 
mechanism of BKPyV inhibition is still undefined, we have some indications that the 
difference of the host cell may play a different role, since the viral replication cycles in 
RPTECs and HUCs were affected at different steps. We also observed that artesunate 
inhibits the replication of JCPyV in COS-7 cells (Paper IV). Also here the inhibition is 
closely connected to a transient inhibition of cell proliferation. Taken together, the work 
shows promising effects of artesunate on BKPyV and JCPyV replication in all cells 
tested, but also some cell type-dependent cytostatic effects. The inhibitory effects 
were seen at concentrations of 1.25 to 10 µM. At very high concentration of ≥ 20 µM, 
some cytotoxic effects were seen. The significance and the potential application of this 







Relevance of the cell culture model 
Before any potential antiviral drug is tested on humans, evaluation of the safety 
and efficacy of the drug should be tested in appropriate cell culture and if possible in 
animal models. Since there is no known animal model for BKPyV or JCPyV replicative 
diseases, the choice of cell culture model is particularly important. For the study of the 
antiviral activity of artesunate on BKPyV replication, we used RPTECs (Paper I) and 
HUCs (Paper III). Both, RPTECs and HUCs represent the target cells of BKPyV in 
pathologies of PyVAN and PyVHC. For the study of JCPyV antiviral, COS-7 cells were 
used, which have been widely used by other researchers because of their 
permissiveness to JCPyV replication (Paper IV). One very important question is if 
these were well justified cell culture model systems.   
For PyVAN, an important part of the pathogenesis is the undisturbed high-level 
BKPyV replication in the kidney tubular epithelial cells. When kidney biopsies from 
patients with PyVAN were examined, BKPyV intranuclear inclusion bodies in epithelial 
cells along the entire nephron i.e. the glomerulus, proximal- and distal convoluted 
tubules, collecting tubules and to a lesser extent the loop of Henle, were observed 
(192, 210). Interestingly, immunohistochemistry also revealed that urothelial cells in 
these patients were infected by BKPyV, although this was clinically silent (210). 
BKPyV was mainly found in superficial transitional cells but occasionally also in basal 
cells. Of note, the infected urothelial cells in PyVAN patients have been suggested to 
account for more than 90% of the urine BKPyV DNA load and can probably influence 
the disease progression due to reflux of virus containing urine into the graft (96). 
Based on this, RPTECs and HUCs seem to be the best model systems to investigate 
the effect of new drugs for a potential future treatment of PyVAN.  Commercially 





up to the 6th passage have been found to provide a similar environment as the cells in 
vivo (reviewed in (46), all experiments with RPTECs were performed with cells at 
passage 4. Apparently, RPTECs remain in a differentiated state with expression of 
organic anion transporters and members of the ATP binding cassette transporter 
family (2, 46, 140). Moreover, BKPyV replication in RPTECs was already 
characterized and RPTECs had been used for several previous antiviral studies (29, 
30, 182, 232, 259). Studies on HUCs have shown that these cells change in culture 
from the transitional epithelial phenotype to a proliferative basal/intermediate cell 
phenotype (141, 181, 264). In line with this, real-time viability monitoring using the 
xCelligence system demonstrated that HUCs proliferated in vitro (Paper II and III), 
although to a lesser extent than RPTECs (Paper I) and COS-7 cells (Paper IV). 
Except for two papers where mixed cells from the urine of newborn infants were 
isolated and infected with BKPyV (24, 89, 238), there was no prior published work on 
BKPyV-infection of primary urothelial cells and we therefore made an effort to 
characterize this in detail (Paper II). To avoid unnecessary cell differentiation and to 
endeavor similar conditions, all experiments with HUCs were performed with cells at 
passage 4.  
For PyVHC, one important factor in the pathogenesis is an uncontrolled high-
level BKPyV replication in urothelial cells. Therefore, primary human urothelial cells 
like HUCs seem to be the best model system for investigation of new antiviral drugs 
for treatment of PyVHC. In fact, in wells with BKPyV-infected HUCs, we observed cells 
rounding up to form decoy-like cells and denuded areas (Paper II), nicely mimicking 
the in vivo situation in an infected bladder. 
PML is caused by the cytopathic replication of JCPyV in the myelin-producing 





often reveal astrocytes staining positive for LTag and sometimes VP1 (10), but these 
cells are probably not productively infected but have taken up virus or cellular and viral 
debris (133). Except for human primary fetal glial cell (218, 219), and brain progenitor-
derived astrocytes (112), hardly any primary human cells are permissive for JCPyV 
(133). Although human primary oligodendrocytes would have been the best cell model 
for our study of artesunate treatment of JCPyV replication, oligodendrocytes are 
difficult to obtain and difficult to propagate unless they are immortalized. Besides this, 
ethical issues, poor availability and cumbersome preparation prevented us from 
preparing primary oligodendrocytes. To try to overcome these obstacles, we ordered 
the immortalized human-human hybrid cell line M03.13 with phenotypic characteristics 
of primary oligodendrocytes (191), but unfortunately we were not able to infect these 
cells with JCPyV MAD-4 (Paper IV). We therefore decided to use the human fetal glial 
cell line SVG p12 (ATCC CRL-8621) derived from human fetal glial cells immortalized 
with a plasmid conferring constitutive SV40 LTag expression (187). Surprisingly, we 
found that these cells contained infectious BKPyV (Appendix II) (127) and they could 
therefore not be used. We kindly requested and received SVG-A cells, a subclone of 
SVG cells, from Professor Walter Atwood at Brown University USA,  and found that 
they were BKPyV negative and therefore could be used (Appendix II). Nevertheless, 
before we started our antiviral study, we decided to compare JCPyV replication in 
SVG-A, HEK 293TT and COS-7 cells (Paper IV), all cell lines that express SV40 LTag 
and are reported to support JCPyV replication (43, 44, 118). We found that HEK 
293TT and COS-7 cells were more permissive for JCPyV MAD-4 than SVG-A, but 
since HEK 293TT were not well attached to the wells, as also noted by others (248), 
we decided to use COS-7 cells for our investigations. Besides, COS-7 cells had 





Artesunate and antiviral targets in BKPyV and JCPyV replication 
There are three main strategies used to combat viral infections: an antiviral drug 
can either target specific viral proteins (viral targets), cellular proteins (host targets) or 
modulate the immune response. In general, antiviral drugs targeting viral proteins 
ensure the specificity and safety but increases the possibility of resistance 
development, while antiviral drugs targeting cellular proteins and modulate immune 
response provoke less resistance development but have a higher risk of side effects 
(214, 244).  
In Paper I, III and IV, we have seen that artesunate inhibits the replication of 
BKPyV and JCPyV, but what do we know about the target and the mechanism for this 
inhibition? Since BKPyV and JCPyV both have a small genome encoding only about 7 
or 9 viral proteins, respectively, they have a limited number of potential viral targets for 
antiviral therapy. The main viral protein of interest for antiviral drug research has been 
the regulatory protein LTag. Some inhibitors of the ATPase activity of SV40 LTag 
(MAL2-11B, bisphenol A and hexachlorophene) are described (251, 252, 288), but a 
significant cytotoxicity limited their further investigations. Fluoroquinolones that 
selectively inhibit bacterial topoisomerase II/IV (11), have been shown to also inhibit 
BKPyV replication (92, 172, 223, 231, 259) and the mechanism for this inhibition was 
speculated to be inhibition of LTag helicase activity as suggested for SV40 LTag (8). 
However, in our previous study, the two fluoroquinolones ofloxacin and levofloxacin 
also reduced cellular DNA replication suggesting that the cellular topoisomerase II 
was also inhibited (259). In Paper I, we reported that artesunate at 10 µM reduced 
BKPyV LTag mRNA and protein expression by 30 and 75%, respectively. The 
reduction of early protein expression is similar to the effect of fluoroquinolones (259) 





Although we can conclude that artesunate reduces BKPyV LTag expression in 
RPTECs (Paper I), it is still undefined whether or not this is a direct or an indirect 
effect. Since all steps in the replication cycle are connected, inhibition of this early step 
inhibits all later steps thereby making it difficult to elucidate any effects of artesunate 
on late steps of the viral replication cycle. In BKPyV-infected HUCs, LTag expression 
was not specifically looked for but was probably not influenced by artesunate since the 
subsequent step, viral DNA replication, was unchanged (Paper III). These results 
suggest an effect of artesunate in HUCs on a step after viral genome replication. In 
Paper IV, where the effect of artesunate on JCPyV replication was investigated in 
COS-7 cells, we did not investigate the affected step(s) in the viral replication cycle 
since the host cells expressed high amounts of SV40 LTag which can initiate JCPyV 
replication (184), thereby complicating the picture.  
Although the small viruses BKPyV and JCPyV depend on multiple cellular 
proteins for their replication, the limited knowledge on the replication cycle has 
delayed the recognition of potential cellular targets for antiviral therapy. R-Roscovitine, 
a cyclin-depedent kinase inhibitor which previously was found to have antiviral activity 
against a wide variety of herpes viruses, was shown to inhibit replication and 
cytopathic effect of JCPyV in vitro (214) and also suppress LTag expression during 
SV40 infection (139). R-Roscovitine has been evaluated in several Phase I and II 
studies where it has shown early signs of anti-cancer activity in approximately 240 
patients and is now in Phase II testing for Cushings Disease (ClinicalTrials.gow 
NCT02160730) but has not yet been tested for viral infections. In our work, artesunate 
was found to induce cytostatic effects in RPTECs, HUCs and COS-7 cells (Paper I, III 
and IV). In RPTECs (Paper I) and COS-7 cells (Paper IV), the cellular DNA 





concentration-dependent manner. In COS-7 cells, DNA replication was measured and 
found reduced already at 24 hours posttreatment (hpt) which may suggest that this 
step was directly affected by artesunate. For RPTECs (Paper I), the DNA replication 
was first measured at 72 hpt and the reduction found could therefore reflect the lower 
cell number as indicated by the real-time viability cell index. However, in Paper I, the 
cell cycle distribution of artesunate treated cells at 24 hpt was investigated in detail by 
flow cytometry and a 50% reduction of the cell population in S phase was found 
confirming the inhibition of cellular DNA replication. In RPTECs, HUCs and COS-7 
cells (Paper I, III and IV), the metabolic activity was investigated by resazurin 
reduction and/or ATP content measurements and was found to be reduced in a 
concentration-dependent manner. In COS-7 cells (Paper IV), the reduction was 
measured already 24 hpt, which could indicate that the metabolic activity per cell was 
directly affected, while for RPTECs (Paper I) and HUCs (Paper III) metabolic activity 
was first measured at 72 hpt and based on the real-time viability cell index probably 
reflected a lower cell number rather than a reduced metabolism per cell.  
Artesunate has shown antiviral activity against a wide variety of herpes viruses in 
vitro with no or little cytotoxicity (Table 2) (83, 155, 195, 247). Although the molecular 
mechanism for the anti-HCMV effect of artesunate is not completely understood, the 
NFĸB or Sp1 dependent activation pathways seems to be inhibited and this inhibits 
the expression of HCMV immediate early genes and the viral DNA replication (17, 83, 
84). We did look for NFĸB expression in BKPyV-infected RPTECs but could not find 
an upregulation due to BKPyV infection as measured by western blot, and artesunate 
did not change the level of NFĸB expression in mock-infected or BKPyV-infected 





by a different mechanism. We have still not investigated the NFĸB expression in 
JCPyV-infected cells. 
Artesunate: a possible future treatment for polyomavirus-associated diseases? 
Though we have found that artesunate can effectively inhibit BKPyV replication 
(Paper I and III) and JCPyV replication (Paper IV) in vitro, an important question is 
whether or not artesunate can be used for the treatment for polyomavirus-associated 
diseases. In addition to being used on millions of malaria patients, artesunate has 
recently been used to treat at least 14 patients with severe HCMV, HSV-2 or HHV-6B 
infections (105, 116, 169, 254, 258, 287) by oral or intravenous daily doses of up to 
200 mg per day for up to 7 months.  Seven of these patients recovered from their viral 
infection and in some of the unsuccessfully treated patients, a reduction of the viral 
load was seen. It should also be emphasized that for most of these patients, 
artesunate treatment was first started when other treatment options had failed. Since 
the EC50 of artesunate for BKPyV replication in RPTECs (4.2 µM), and in HUCs (6.2 
µM) (Paper I and III) and for JCPyV replication in COS-7 cells (3.0 µM) (Paper IV) is 
in the same range as reported for herpes viruses (2.16–7.21 µM) (Table 2), 
artesunate treatment of BKPyV and JCPyV infections seems to be a possible. 
To treat PyVAN, artesunate and/or the active metabolite dihydroartemisinin, 
must reach the kidney tubular epithelial cells and the urothelial cells. After intravenous 
administration of artesunate at a dosage of 0.5-8 mg/kg to healthy volunteers and 
malaria patients, peak plasma concentration of artesunate in the range of 12.5-217 µM 
(4.8-83.3 µg/ml) have been reported (22, 142, 174, 208) indicating that the EC50 
concentration of artesunate at least is achievable in the plasma. The fate of artesunate 
in the kidneys is still not well known. Based on a rat model and one case study of an 





passage through the glomerulus (49, 253). However, since only small amounts of 
artesunate and dihydroartemisinin are detected in the urine, this suggests that most of 
the filtered artesunate is reabsorbed from the tubules (143, 290, 294) and therefore 
should enter the tubular epithelial cells.  
To treat PyVHC, artesunate and/or dihydroartemisinin needs to reach the 
affected sites in the urinary bladder. However, since the urothelium is multilayered, 
and the superficial transitional cells are hardest affected (210), we speculate that 
treatment from the apical i.e. urine side would be more efficient than via blood from 
the basolateral side. Although we have no information about artesunate uptake in 
urothelial cells in vivo, in the human intestinal epithelial cell line Caco-2, artesunate 
was found to enter the cells by passive diffusion (18) suggesting that artesunate could 
enter the cell from either side. Since only small amounts of artesunate and 
dihydroartemisinin are found in urine after intravenous administration, intravesical 
delivery of artesunate could possibly be one option. Although this has not been done 
before, the method has been used to administer other drugs to treat bladder cancer 
and cystitis (275).  Moreover, intravesical delivery of cidofovir was used to treat 26 
PyVHC patients (185) but while the patients improved clinically, a virologic response 
was missing. Our in vitro results suggest that the uptake of artesunate in HUCs 
(Paper III) is slower than uptake in RPTECs (Paper I) and COS-7 cells (Paper IV) but 
this can be different in vivo. Interestingly, it has been reported that absorption of 
instilled chemotherapeutic drugs can be enhanced by dimethyl sulfoxide (DMSO) 
(107). Since artesunate was dissolved in DMSO and since we found no 
disadvantageous effects of DMSO on HUCs viability (Paper III), intravesical delivery 





To treat PML, artesunate and/or dihydroartemisinin needs to reach the affected 
sites in the brain. Very limited information is available about penetration of artesunate 
into the CNS. In a rat model, artesunate was found to cross the blood-brain barrier 
after intravenously administration of 5 mg/ml/kg, but only about 1% of the total dose 
was detected in the brain and even less in plasma (176, 294). However, as mentioned 
in Paper IV, in one study of six plasmodium falciparum malarial patients treated 
intravenously with artesunate (66), no artesunate was detected in CSF but the 
concentration of dihydroartemisinin increased over time. Although this study has 
several limitations such as the number of patients included, that only one time point for 
each patient was examined and that the patients had malaria, it suggests that 
dihydroartemisinin is accumulated in the CSF and possibly can enter the brain. This is 
also supported by a study of plasmodium bergheri-infected mice (196), where a single 
dose of artesunate (32 mg/kg) improved survival and clinical signs of cerebral malaria. 
Although a large number of patients have been treated with artesunate without 
reported neurotoxicity, it will be important to monitor effects on the brain especially 
when doses exceeding the malaria defined doses are used. Interestingly, while TNF-α 
has been shown to induce the expression of LTag in IMR-32 cells and thereby 
contribute to JCPyV replication (211), artesunate was found to reduce the expression 
of TNF-α in the brain of mice with cerebral malaria (265). If this is also the case in 
human brains, this would be one mechanism for artesunate to reduce JCPyV 
replication.  
If artesunate ever will be used for the treatment of PML for instance in HIV 
positive patients, it is important to be aware of possible interaction between artesunate 






Future perspectives  
As a strategy to improve the activity and the compliance of artesunate, two 
artemisinin units were connected into a stable dimeric molecule for single dose 
therapy (reviewed in (202)).  Eighteen different artemisinin-derived dimers with potent 
anti-HCMV properties have been described (13, 122-124, 202). As for the monomer, 
the activity seems to be connected to their typical endoperoxide bridge (123). Of note, 
the artemisinin-derived dimers were found to have upto 500 fold higher activity against 
HCMV replication than the artemisinin monomers like artesunate (13) and could 
therefore be used in nanomolar (nM) concentrations. Interestingly, the artemisinin-
derived dimers inhibited HCMV replication irreversibly and the inhibition was shown at 
an early stage of the viral replication cycle, on DNA replication and also on steps post 
DNA replication (124). Apparently, the dimers were not toxic to the host cells at the 
concentrations required to completely inhibit HCMV replication. In malaria infected 
mice, the dimers in combination with mefloquine increased survival significantly 
compared to treatment with the monomer artemether in combination with mefloquine 
(60). It would be very interesting to investigate the effect of artemisinin-derived dimers 
on BKPyV and JCPyV replication. 
For some patients with HCMV infection, treatment with artesunate was given for 
4 to 7 months (105). Probably the treatment period could have been shortened if the 
half-life of the drug was increased and the delivery improved. In the early 1990s, solid 
lipid microparticles were developed as a drug carrier system with sustained release 
(review in (53)). Recently, artesunate was formulated with lipid excipients as solid lipid 
microparticles (53). These microparticles showed good sustained release properties, 
could be administrated once daily and showed superior antimalarial properties over 





showed that artesunate had rapid but reversible effect on BKPyV replication in 
RPTECs (Paper I, Figure 5A), the microparticles keeping a more constant artesunate 
concentration could be an attractive delivery vehicle and should be considered for 
future studies. 
Combination therapy is now increasingly used for the treatment of cancer, 
tuberculosis, HIV, hepatitis C  virus and malaria but has not been common for 
treatment of polyomavirus-associated diseases. Importantly, the drug combination 
must have synergistic effect. Recently, the Bliss model (32) was suggested to study 
the synergistic, antagonistic or additive effects of anti-HCMV drugs in vitro (48). This 
model could be used to study the anti-BKPyV and anti-JCPyV effect of artesunate in 
combination with other drugs. The effect of several drugs like fluoroquinolones, 
cidofovir, leflunomide and CMX001 on BKPyV replication in RPTECs (29, 30, 232, 
259) and CMX001 on JCPyV replication in primary human astrocytes (112) have 
previously been characterized. Based on these results, the known organ distribution 
and safety profile, we would like to investigate the combination of artesunate and 
fluoroquinolones on BKPyV replication; and artesunate and CMX001 on JCPyV 
replication. If synergistic effects were found without increased cytotoxicity, the efficacy 










We have found that artesunate can inhibit the replication of BKPyV and JCPyV in 
cell culture, and that this inhibition is closely connected to cytostatic effects suggesting 
a mechanism affecting cellular proteins. We have performed our studies in appropriate 
cell model systems for BKPyV but a less relevant cell model for JCPyV since authentic 
cells were not available. However, since the EC50 found was similar for BKPyV and 
JCPyV and since these viruses are closely related, we think that also JCPyV 
replication in other cells will be inhibited by artesunate. Taken together with the EC50 
found for herpes viruses, the described organ distribution and safety of artesunate, we 
think that artesunate or a modified form of artesunate or artesunate in combination 
with one of the adjunctive drugs in use could be beneficial for treatment of PyVAN, 
PyVHC and PML. By pursuing artesunate as an antiviral treatment option, we can 
greatly benefit from the ongoing artesunate research and the clinical studies on 
malaria patients that are taking place. Finally, carefully designed clinical studies have 
to be performed in patients suffering from PyVAN, PyVHC and PML to answer if 
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